MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
The Senior Manager of Publications manages external publication vendors as well as edits medically relevant scientific presentations (i.e., clinical, scientific, and health economics, abstracts, posters, and oral presentations) to fulfill scientific and medical objectives, in accordance with authors’ direction and in adherence to Publication Policy Procedures and ICMJE and GPP3 guidelines. Assists with the creation of other scientific documents (e.g., medical science liaison [MSL] training slide decks, training tools, and FAQs). Communicates effectively with external authors and internal stakeholders and presents project updates to Executive Director of MRX/BAP/ZILU GMAT Team, Senior Vice President of Medical Affairs, and Mirum Senior Leadership.
JOB FUNCTIONS/RESPONSIBILITIES
Key Responsibilities:
- Understand scientific and medical content in given areas of the company.
- Review and edit scientific content for oral and poster presentations at congresses.
- Manage publications vendor and work closely with key internal and external stakeholders.
- Implement the publication management system.
- Development of scientific training tactics (eg, internal training MSL decks, tools, FAQs).
- Engage internal and external subject matter experts, when appropriate, for participation in scientific communication tactics and content development.
- Manage and contribute to global publication and scientific communications plans for the company needs.
Other Responsibilities:
- Work effectively with our Medical Communications and Publications Agencies on publication strategies and deliverables.
- Learn and apply knowledge of therapeutic area data to scientific publishing projects focused on congress presentations.
- Operationally execute all activities to agreed timelines related to the preparation of scientific medical publications (i.e., medical, scientific, and health economics abstracts, posters, and oral presentations).
- Assist with Medical Legal and Regulatory (MLR) Committee review and approvals as appropriate.
- Interface with external experts (e.g., physicians, other health care professionals) and effectively collaborate with Clinical Research and Development colleagues, along with other Mirum stakeholders including, but not limited to, Compliance, Safety, Biostatistics, Clinical Operations, and the Commercial group to ensure accurate and timely completion/delivery of information, including addressing conflicting demands, and review of scientific presentations and training programs.
QUALIFICATIONS
Education /Experience:
- Advanced degree with 3+ yrs. experience in scientific communication, training, and/or publications planning and development in an agency or pharmaceutical environment or applicable experience working in pharmaceutical environment with transferable skill set.
- Demonstrated strong project management skills and leadership poise a must to negotiate and facilitate alignment amongst internal and external stakeholders (KOLs, authors, cross functional teams).
- Experience working with cross-functional stakeholders and/or agencies to develop abstracts, posters, and oral presentations.
- Excellent and effective interpersonal and communication skills.
- Must be well organized and able to multi-task in a fast-paced deadline driven environment
- Demonstrated experience managing vendors and budgets.
Knowledge, Skills and Abilities:
- Advanced computer and Internet skills, including knowledge of MS applications such as Word, PowerPoint, Excel, Veeva RIM, electronic publication management tools (e.g., PubStrat and Datavision), references databases (e.g., EndNote), PubMed, etc.
- Ability to travel (US and International) approximately 30% of time.
The salary range for this position is $170,000 to $190,000 USD. Compensation will be determined based on several factors including, but not limited to; skill set, years of experience, and the employee’s geographic location. Please note that the required compensation details listed in US role postings reflect the base salary only, and do not include bonus, equity, or benefits unless otherwise provided.
#LI-HYBRID
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Skills Required
- Advanced degree with 3+ years experience in scientific communication, training, or publications planning in agency or pharmaceutical environment
- Demonstrated strong project management skills and leadership poise to negotiate and align internal and external stakeholders
- Experience developing abstracts, posters, and oral presentations with cross-functional stakeholders or agencies
- Excellent interpersonal and communication skills
- Well organized and able to multi-task in a fast-paced, deadline-driven environment
- Demonstrated experience managing vendors and budgets
- Knowledge of MS applications (Word, PowerPoint, Excel) and advanced computer/internet skills
- Experience with Veeva RIM and electronic publication management tools (e.g., PubStrat, Datavision)
- Familiarity with reference databases and literature tools (EndNote, PubMed)
- Ability to travel US and International approximately 30% of the time
Mirum Pharmaceuticals Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Mirum Pharmaceuticals and has not been reviewed or approved by Mirum Pharmaceuticals.
-
Equity Value & Accessibility — Equity grants to new hires and an employee stock purchase plan make ownership more accessible and can boost total rewards when performance is strong. Public disclosures highlight frequent option/RSU inducements.
-
Healthcare Strength — Comprehensive medical, dental, and vision coverage is employer-paid for employees, with added life, disability, and EAP support. This combination reduces financial burden and enhances overall wellbeing.
-
Leave & Time Off Breadth — A broad time-off program includes multiple paid company holidays, a year-end shutdown, accrued vacation, and paid parental leave. This breadth provides additional rest periods beyond standard vacation.
Mirum Pharmaceuticals Insights
What We Do
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
